Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
26.35
-0.39 (-1.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akero Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 04, 2024
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Akero Therapeutics: Q4 Earnings Insights
February 29, 2024
Via
Benzinga
11 Analysts Have This to Say About Akero Therapeutics
November 14, 2023
Via
Benzinga
Akero Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
February 29, 2024
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Why Akero Therapeutics Shares Are Slumping This Week
October 12, 2023
Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.
Via
The Motley Fool
Analyst Ratings for Akero Therapeutics
October 11, 2023
Via
Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
February 23, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
November 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 08, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
October 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
October 13, 2023
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance...
Via
Benzinga
E2open, Sharecare And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
October 12, 2023
U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward
October 11, 2023
Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 11, 2023
Via
Benzinga
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
October 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 11, 2023
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in...
Via
Benzinga
Why Shares of 89bio Plummeted on Tuesday
October 10, 2023
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Via
The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
October 10, 2023
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to
Via
Benzinga
Crude Oil Moves Lower; Neogen Posts Downbeat Results
October 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.